Home   Drug Development   Newsroom   About ReceptoPharm   Contact
» Overview
» Management Team
» Advisors
» Corporate Presentation
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More

About ReceptoPharm

ReceptoPharm was incorporated as Receptogen in the United States under the laws of the State of Nevada on June 4, 2001 for the purpose, among other things, of developing and acquiring patents based upon advanced receptor and molecular biology. The name was changed to ReceptoPharm in April of 2003 and the company was licensed to do business in the State of Florida. In March of 2008, ReceptoPharm became a wholly-owned subsidiary of Nutra Pharma Corporation


ReceptoPharm is engaged in the discovery and development of novel and off-patent peptide technologies primarily for the prevention and treatment of disease in humans. The emphasis of ReceptoPharm's approach to the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature. The Company's primary focus is on the treatment of viral and neurological diseases.

With its' large volume of research and preclinical data ReceptoPharm believes it has identified a number of therapeutic products that have the capability to provide significant benefits for patients with such diseases as multiple sclerosis (MS), adrenomyeloneuropathy (AMN), human immunodeficiency virus (HIV), myasthenia gravis (MG), pain, and other disorders.

ReceptoPharm's principal executive offices, manufacturing, research and development facilities are located Plantation, Florida.

Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name: